Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Applied Molecular Transport Inc is a biotechnology business based in the US. Applied Molecular Transport shares (AMTI) are listed on the NASDAQ and all prices are listed in US Dollars. Applied Molecular Transport employs 100 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$22.75|
|52-week range||$20.50 - $78.22|
|50-day moving average||$25.72|
|200-day moving average||$37.18|
|Wall St. target price||$75.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.23|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-17)||N/A|
|1 month (2021-09-28)||-16.54%|
|3 months (2021-07-28)||-22.51%|
|6 months (2021-04-28)||-57.67%|
|1 year (2020-10-27)||-29.22%|
|2 years (2019-10-24)||N/A|
|3 years (2018-10-24)||N/A|
|5 years (2016-10-24)||N/A|
|Gross profit TTM||$-32,995,000|
|Return on assets TTM||-25.2%|
|Return on equity TTM||-42.85%|
|Market capitalisation||$884.5 million|
TTM: trailing 12 months
There are currently 2.4 million Applied Molecular Transport shares held short by investors – that's known as Applied Molecular Transport's "short interest". This figure is 8.3% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting Applied Molecular Transport shares can be evaluated.
Applied Molecular Transport's "short interest ratio" (SIR) is the quantity of Applied Molecular Transport shares currently shorted divided by the average quantity of Applied Molecular Transport shares traded daily (recently around 158514.7606383). Applied Molecular Transport's SIR currently stands at 15.04. In other words for every 100,000 Applied Molecular Transport shares traded daily on the market, roughly 15040 shares are currently held short.
However Applied Molecular Transport's short interest can also be evaluated against the total number of Applied Molecular Transport shares, or, against the total number of tradable Applied Molecular Transport shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Applied Molecular Transport's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Applied Molecular Transport shares in existence, roughly 60 shares are currently held short) or 0.1426% of the tradable shares (for every 100,000 tradable Applied Molecular Transport shares, roughly 143 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Applied Molecular Transport.
Find out more about how you can short Applied Molecular Transport stock.
We're not expecting Applied Molecular Transport to pay a dividend over the next 12 months.
Applied Molecular Transport Inc. , a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.